NAD+, MOTS-c and epitalon haven’t answered the same question
NAD+, MOTS-c and epitalon often appear in the same longevity conversation. That doesn’t make them three versions of one treatment. I find the comparison more useful when it shows what each finding actually tells us, rather than trying to name a winner.
The actual material comes first
NAD+ is a coenzyme, a helper molecule for enzymes. NMN and NR are ingredients the body can use to make it. MOTS-c is a short peptide with instructions in mitochondrial DNA, inside the cell’s energy-making structures; epitalon is a lab-made peptide related to the gland extract Epithalamin.
Those names need to stay attached to their results. If an experiment tested an ingredient used to make NAD+, that isn’t a test of every NAD+ preparation. If it tested a gland extract, the nearby peptide doesn’t get the credit.
NAD+ precursors
Precursors are ingredients the body can turn into NAD+. Human trials have tested them, and the review of clinical evidence finds limited overall benefit despite measurable responses. The useful question is what that ingredient improved for the people studied.
MOTS-c
The exercise paper measured people’s own MOTS-c after exercise and tested added MOTS-c in mice. The mouse performance result doesn’t establish a human treatment benefit. Those two parts of the paper need to stay separate.
Epitalon
The telomere finding came from human cells in a dish. The older human longevity report used Epithalamin, the extract. Neither gives synthetic epitalon a demonstrated human longevity benefit. Similar spelling can make that difference surprisingly easy to miss.
A useful benefit needs a human job
Walking farther, sleeping better or finding an ordinary task easier would be changes people could notice. Evidence about those outcomes matters. Learning how a molecule works in a cell can help explain why a treatment might work, while leaving its real-life benefit unanswered.
The starting material matters here, too. Epithalamin came from cattle pineal glands. That’s the extract used in the older human longevity report. The human setting doesn’t turn it into evidence about synthetic epitalon.
The older human report used Epithalamin from cattle pineal glands. A synthetic peptide can’t inherit the extract’s results.
I’d want a comparison to name the hoped-for benefit before ranking anything. Then I can ask what people received, who was studied and how long the improvement lasted. A podium is rather premature if we haven’t agreed on the event.
Safety can’t be averaged into a score
Short NAD+ precursor trials leave long-term safety questions open. MOTS-c and epitalon don’t have an established human safety profile or FDA approval. Compounded medicines aren’t FDA-approved either. These gaps deserve their own attention, rather than a reassuring overall rating.
None of these findings proves that a treatment makes people live longer. That’s a reason to make the claim clearer, not to abandon curiosity. I’d rather leave with a useful question than a winner whose evidence has gone missing along the way.